Letrozole Actavis (Letrozole)

Letrozole works by inhibiting the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By blocking this conversion, estrogen levels fall, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing disease progression.

The dose of Letrozole Actavis is determined by the prescribing physician based on the patient’s clinical condition, disease stage and treatment guidelines. Typical dosing ranges are described in professional references, but the exact regimen must be individualized by a qualified healthcare professional.

Letrozole is contraindicated in pregnancy because it can interfere with fetal development by lowering estrogen levels. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant. Effective contraception is required for women of child‑bearing potential.

To order Letrozole Actavis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, oncology centres, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Letrozole, anastrozole and exemestane belong to the same class of aromatase inhibitors. Letrozole is often considered the most potent inhibitor of estrogen synthesis, which can translate into slightly higher efficacy in some trials, but individual response varies. Safety profiles are similar, with bone loss and hot flashes being common across the class.

Letrozole Actavis tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Letrozole Actavis is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their physician and should not alter the dose or frequency without medical advice.

Serious risks of Letrozole include significant bone loss leading to osteoporosis or fractures, increased risk of thromboembolic events such as deep‑vein thrombosis, and rare but severe liver function abnormalities. Patients should be monitored regularly for bone density, cardiovascular health and hepatic enzymes.

Letrozole should not be used by pregnant women, nursing mothers, or individuals with known hypersensitivity to letrozole or any excipients. Caution is also advised for patients with severe liver impairment, uncontrolled cardiovascular disease, or a history of thromboembolic disorders, as the drug may exacerbate these conditions.